News & Blog

Lexeo Announces FDA Clearance of IND Application for LX2006 for Friedreich’s Ataxia Cardiomyopathy

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006

Larimar Therapeutics Announces $95 Million Private Placement Financing

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

Lexeo Therapeutics Announces License Agreement and Consolidation of Pre-Clinical Data Package

Lexeo Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia